Rapid desensitization for hypersensitivity reactions to chemotherapeutic drugs; a case series

Document Type: Research article

Authors

1 Department of Immunology and Allergy, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Department of Pediatric Hematology and Oncology, Loghman-e- Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Department of Immunology and Allergy, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Department of Pediatrics, Loghman-e- Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

6 Department of Pediatrics, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

7 Department of Immunology and Allergy, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Usage of cancer chemotherapeutics drugs can be associated with adverse drug reactions. When IgE-mediated drug reactions are formed following administration of a chemotherapeutic drug that is a drug of choice, drug desensitization protocols can be helpful. Hypersensitivity reactions can be allergic or nonallergic, but the clinical manifestations are similar. Rapid drug desensitization (RDD) is effective when used appropriately, however it is often over utilized instead of performing a drug challenge. RDD is both an acceptable approach and a high-risk treatment modality in patients in whom the first line chemotherapy is the offending agent. The sa